Capricor Therapeutics (CAPR) Revenue (2016 - 2024)
Historic Revenue for Capricor Therapeutics (CAPR) over the last 16 years, with Q4 2024 value amounting to $28.9 million.
- Capricor Therapeutics' Revenue rose 13874.78% to $28.9 million in Q4 2024 from the same period last year, while for Sep 2025 it was $28.9 million, marking a year-over-year increase of 190.27%. This contributed to the annual value of $40.0 million for FY2024, which is 5886.84% up from last year.
- Capricor Therapeutics' Revenue amounted to $28.9 million in Q4 2024, which was up 13874.78% from $2.3 million recorded in Q3 2024.
- In the past 5 years, Capricor Therapeutics' Revenue ranged from a high of $28.9 million in Q4 2024 and a low of $16863.0 during Q3 2020
- For the 5-year period, Capricor Therapeutics' Revenue averaged around $4.6 million, with its median value being $1.9 million (2022).
- In the last 5 years, Capricor Therapeutics' Revenue plummeted by 8813.06% in 2020 and then skyrocketed by 115930.32% in 2023.
- Quarter analysis of 5 years shows Capricor Therapeutics' Revenue stood at $57830.0 in 2020, then surged by 252.9% to $204082.0 in 2021, then surged by 370.35% to $959903.0 in 2022, then soared by 1159.3% to $12.1 million in 2023, then skyrocketed by 138.75% to $28.9 million in 2024.
- Its Revenue stands at $28.9 million for Q4 2024, versus $2.3 million for Q3 2024 and $4.0 million for Q2 2024.